The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects.
作者信息
Alarayyed N A, Graham B R, Prichard B N, Smith C C
机构信息
Department of Medicine, University College London Medical School, Rayne Institute.
Aggregation in platelet-rich plasma from normotensive men was induced by adrenaline (0.25-16 microM), ADP (0.25-16 microM), collagen (0.25-8 micrograms ml-1) or serotonin (10 microM) alone, or by previously sub-threshold concentrations of adrenaline (0.03-1 microM) in combination with sub-threshold concentrations of serotonin (2.5 microM), ADP (0.5 microM) or collagen (0.125 micrograms ml-1). The effects of the alpha 1-adrenoceptor blockers naftopidil and doxazosin on platelet aggregation were investigated. 2. The dose-response curves for collagen and ADP were unaffected by either drug. However, naftopidil (40 microM) inhibited serotonin-induced platelet aggregation (23.9%, 95% confidence interval (CI) 10.7 to 37.1%; P < 0.01) and caused a slight shift to the right of the adrenaline dose-response curve with a mean increase in the EC50 value of 0.5 microM (95% CI 0.07 to 0.93 microM; P < 0.05). Doxazosin had no effect on serotonin or adrenaline-induced aggregation. 3. A marked potentiation of the aggregation induced by subthreshold concentrations of adrenaline resulted from the prior addition of low concentrations of ADP, collagen or serotonin. 4. These potentiated responses were inhibited in a dose-dependent manner by naftopidil and to a lesser extent doxazosin. The maximum inhibitions (%) produced by naftopidil (40 microM) on the responses of adrenaline potentiated by ADP were 58.3% (95% CI 36.8 to 79.8%; P < 0.001), serotonin 58.9% (95% CI 40.0 to 77.8%; P < 0.001), and collagen 70.9% (95% CI 52.5 to 89.3%; P < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
摘要
正常血压男性富含血小板血浆中的聚集可由单独的肾上腺素(0.25 - 16微摩尔)、二磷酸腺苷(ADP,0.25 - 16微摩尔)、胶原蛋白(0.25 - 8微克/毫升)或血清素(10微摩尔)诱导,也可由先前低于阈值浓度的肾上腺素(0.03 - 1微摩尔)与低于阈值浓度的血清素(2.5微摩尔)、ADP(0.5微摩尔)或胶原蛋白(0.125微克/毫升)联合诱导。研究了α1 - 肾上腺素能受体阻滞剂萘哌地尔和多沙唑嗪对血小板聚集的影响。2. 胶原蛋白和ADP的剂量 - 反应曲线不受这两种药物中任何一种的影响。然而,萘哌地尔(40微摩尔)抑制血清素诱导的血小板聚集(23.9%,95%置信区间(CI)10.7至37.1%;P < 0.01),并使肾上腺素剂量 - 反应曲线轻度右移,EC50值平均增加0.5微摩尔(95% CI 0.07至0.93微摩尔;P < 0.05)。多沙唑嗪对血清素或肾上腺素诱导的聚集无影响。3. 预先添加低浓度的ADP、胶原蛋白或血清素会导致低于阈值浓度的肾上腺素诱导的聚集显著增强。4. 这些增强的反应被萘哌地尔以剂量依赖性方式抑制,多沙唑嗪的抑制程度较小。萘哌地尔(40微摩尔)对由ADP增强的肾上腺素反应产生的最大抑制率(%)为58.3%(95% CI 36.8至79.8%;P < 0.001),对血清素增强的反应为58.9%(95% CI 40.0至77.8%;P < 0.001),对胶原蛋白增强的反应为70.9%(95% CI 52.5至89.3%;P < 0.001)。(摘要截断于250字)